Over the past few weeks, many parents and patients have asked a similar question, often cautiously: should we be concerned about the government’s review of ADHD and autism services?
The concern is understandable. Headlines referencing rising diagnosis rates, NHS pressures, scrutiny of neurodevelopmental services and discussions around disability benefits can easily feel as though they are casting doubt on ADHD and autism themselves.
For those who have spent years waiting for answers, or who finally gained clarity through diagnosis, that interpretation can be unsettling. Some people have told me they worry diagnoses made during the pandemic may now be viewed differently, particularly given how unusual that period was.
During The First Year Of COVID
Global rates of anxiety and depression rose significantly. Isolation, disrupted routines and reduced social interaction shaped daily life in ways that were far removed from typical educational and developmental environments. It is not surprising that some people now wonder whether assessments carried out during that time might be questioned. At present, there is no indication that this is the case.
The review announced in December 2025 by the Department of Health and Social Care is focused on how services are functioning, not on rewriting diagnostic criteria or revisiting existing diagnoses. ADHD and autism continue to be assessed using internationally recognised frameworks such as DSM-5 and ICD-11, which underpin NICE guidance and NHS practice across the UK. There are no proposals to invalidate diagnoses made before, during or after the pandemic.
What’s Under Examination?
NHS England’s own ADHD Taskforce report described services as fragmented and overstretched. Data from NHS sources and parliamentary committees has consistently pointed to long waiting lists and considerable regional variation in access to assessment and support. In many areas, people wait years for an appointment. Services that were originally designed for far smaller numbers are now trying to support hundreds of thousands of individuals. In that context, review is inevitable. It reflects strain on infrastructure, not uncertainty about the science.
The visible increase in referrals has added to public debate. Some commentary has focused on ideas such as overdiagnosis, social media influence or cultural trends. While these explanations circulate widely, they do not fully account for the scale of demand clinicians are seeing. A more grounded explanation is that awareness has improved.
Compared with ten or twenty years ago, teachers, parents and primary care professionals are better informed about neurodevelopmental differences. That has led to more children being referred earlier. It has also enabled adults who were overlooked in childhood to seek assessment later in life. Many people now presenting for diagnosis are not newly affected; they were simply previously unrecognised.
The more pressing difficulties tend to emerge after diagnosis. In ADHD care, delays in medication titration, inconsistent shared care arrangements between NHS and private providers, and regional commissioning differences create uncertainty for patients. Some Integrated Care Boards have clarified that shared care agreements are not automatic, leaving individuals unsure who will manage ongoing prescriptions.
For Autism
The gap often lies in post-diagnostic support. Families may receive a formal diagnosis but struggle to access clear guidance on adjustments, interventions or resources. These are operational shortcomings within service delivery. They are not evidence that ADHD or autism are being mischaracterised.
Alongside this, broader debates about disability benefits and employment have intensified. Rising numbers of working-age adults receiving health-related benefits have prompted political discussion about welfare reform. Although these debates are separate from clinical diagnostic frameworks, the overlap in headlines can make it feel as though questions about public spending are spilling into questions about legitimacy.
In clinical practice, what I see daily are the effects of delayed or fragmented care: heightened anxiety, exhaustion, disrupted education, strain within families, and growing mistrust in systems that are meant to provide support. A careful, evidence-based diagnosis does not create these difficulties. It helps people understand long-standing challenges and move towards appropriate support.
Quality Remains Central
Assessments that follow NICE guidance, are conducted by appropriately qualified clinicians and include clear post-diagnostic planning are essential. Improving how services are delivered is precisely what the review aims to address.
For those waiting for assessment or already diagnosed, it is worth holding onto a few simple facts. There is no policy proposal to invalidate diagnoses. ADHD and autism remain clinically recognised, evidence-based conditions. The review concerns access and service delivery. That said, variation in waiting times and local arrangements may continue while systems adapt to demand.
Continuity Of Care Is Important
Understanding how your local pathway operates, clarifying prescribing arrangements and asking about follow-up planning can make a practical difference, particularly where NHS and private services intersect.
The increased visibility of ADHD and autism in public conversation reflects greater openness around neuro-developmental differences and mental health. That is a constructive shift. Service pressures deserve attention, but they should not be mistaken for doubt about the conditions themselves. Strengthening pathways, rather than questioning diagnoses, is where effort is most productively directed.
Collaborative Post
Leave a Reply